World's Best Scientists 2026 revealed!
Award Badge
Medicine
Poland
2026

D-Index & Metrics

Medicine

D-Index
109
Citations
79791
World Ranking
5650
National Ranking
5

Research.com Recognitions

  • 2026 - Research.com Medicine in Poland Leader Award
  • 2025 - Research.com Medicine in Poland Leader Award
  • 2023 - Research.com Medicine in Poland Leader Award
  • 2022 - Research.com Medicine in Poland Leader Award

Overview

Piotr Rutkowski is affiliated with the Maria Sklodowska-Curie National Research Institute of Oncology in Poland. Their research primarily focuses on the field of Medicine, with a notable emphasis on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Immunology, and Rheumatology.

The areas of study and scientific topics covered in Rutkowski's work include:

  • Sarcoma Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Melanoma and MAPK Pathways
  • Cutaneous Melanoma Detection and Management
  • Immunotherapy and Immune Responses
  • Gastrointestinal Tumor Research and Treatment

Rutkowski's publications have appeared in various academic venues, with frequent contributions to:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Oncology in Clinical Practice
  • Cancers
  • European Journal of Cancer

Notable recent papers authored or co-authored by Rutkowski include:

  • Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma, 2021, New England Journal of Medicine
  • Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial, 2020, The Lancet
  • Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma, 2022, Zurich Open Repository and Archive (University of Zurich)
  • Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology

Frequent co-authors collaborating with Rutkowski include:

  • Anna M. Czarnecka
  • Paolo A. Ascierto
  • Anna Szumera-Ciećkiewicz
  • Georgina V. Long
  • Dirk Schadendorf

Best Publications

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Nivolumab in previously untreated melanoma without BRAF mutation.

    Caroline Robert;Georgina V. Long;Benjamin Brady;Caroline Dutriaux

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary

  • Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

  • Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

    Keith T. Flaherty;Caroline Robert;Peter Hersey;Paul Nathan

  • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

    Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

  • Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

    K T Flaherty;C Robert;P Hersey;P Nathan;P Nathan

  • Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

    Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay

  • Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.

    Frank Stephen Hodi;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

    Caroline Robert;Jean J Grob;Daniil Stroyakovskiy;Boguslawa Karaszewska

  • Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts

    Heikki Joensuu;Aki Vehtari;Jaakko Riihimäki;Toshirou Nishida

  • Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

    Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi

  • Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    P.G. Casali;N. Abecassis;S. Bauer;R. Biagini

  • Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.

    Sant Chawla;Robert Henshaw;Leanne Seeger;Edwin Choy

  • Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.

    Ralf Gutzmer;Daniil Stroyakovskiy;Helen Gogas;Caroline Robert

  • Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

    Paul Nathan;Jessica C. Hassel;Piotr Rutkowski;Jean-Francois Baurain

Frequent Co-Authors

Alessandro Gronchi
Alessandro Gronchi University of Milan
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Jean-Yves Blay
Jean-Yves Blay Claude Bernard University Lyon 1
Caroline Robert
Caroline Robert University of Paris-Saclay
Paolo G. Casali
Paolo G. Casali University of Milan
Peter Hohenberger
Peter Hohenberger Heidelberg University
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Chandrajit P. Raut
Chandrajit P. Raut Brigham and Women's Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in Medicine opens the door to numerous healthcare pathways—including flexible options through online degrees. With increasing demand for skilled nurses and healthcare professionals, online programs offer an accessible route to advance your education while balancing work or family commitments.

Many students look for the cheapest np school online to become a Nurse Practitioner, allowing them to gain advanced clinical skills with minimal financial burden. Similarly, understanding how much is online nursing school can help future nurses budget wisely for their education.

Professionals aiming for leadership or academic roles might consider reputable online nursing doctoral programs that accommodate busy schedules without sacrificing quality. For registered nurses seeking career advancement, affordable rn to bsn programs provide a streamlined and cost-effective way to earn a bachelor’s degree.

Online healthcare degrees create diverse career options, from clinical roles to administration. Carefully research program costs, accreditation, and flexibility to find the right fit for your goals.

Best Scientists Citing Piotr Rutkowski

Trending Scientists

Recently Published Articles